Zydus Lifesciences Limited has announced its acquisition of an 85.6% controlling stake in Amplitude Surgical SA, a leading French MedTech company specializing in orthopedic solutions. This strategic move strengthens Zydus’ presence in the global medical technology industry.
Acquisition Details
The acquisition, valued at €256.8 million, is based on a share price of €6.25 per equity share. Upon completion of the initial block acquisition, Zydus will initiate a mandatory cash tender offer for the remaining 14.4% shares, aiming for full ownership at a total valuation of €300 million. The company’s long-term plan includes a squeeze-out process to delist Amplitude Surgical from Euronext Paris.
Strategic Benefits
Amplitude Surgical, established in 1997, specializes in lower-limb orthopedic implants and solutions. With a global footprint spanning France, Brazil, Australia, Germany, Switzerland, Belgium, and South Africa, the company recorded a turnover of €106 million in FY2024.
This acquisition aligns with Zydus’ strategy to expand into MedTech innovations, leveraging Amplitude Surgical’s advanced product portfolio and global distribution network. The move will enhance Zydus’ market positioning in orthopedics, complementing its established presence in life sciences and wellness.
Regulatory Approvals & Timeline
The transaction is subject to approval from the French Minister of Economy and consultation with Amplitude Surgical’s Social and Economic Committee. The acquisition process is expected to be completed by mid-2025, pending regulatory clearances.
